[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363389-105":59,"doc-detail-363389-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prostate-specific-antigen-testing-and-prostate-cancer-related-outcomes-a-danish-nationwide-study","Prostate-specific antigen testing and prostate cancer-related outcomes: a Danish nationwide study","","Objective evaluates prostate-specific antigen (PSA) testing and prostate cancer-related outcomes within a national, publicly funded healthcare setting, emphasizing restrictive guidance against testing asymptomatic men. Subjects and methods link Danish nationwide registries for men born 1920–1970, followed through 31 December 2023, estimating age-standardised PSA use and cumulative incidences at 100 years for testing, histology, biopsy, diagnosis, and prostate cancer-specific death. Results show high PSA testing rates, especially in older age groups, with substantial cumulative risks through diagnostic pathways. Conclusions support reconsidering PSA availability to reduce harms from unnecessary testing despite active GP training and guidelines.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prostate-specific-antigen-testing-and-prostate-cancer-related-outcomes-a-danish-nationwide-study/363389/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prostate-specific-antigen-testing-and-prostate-cancer-related-outcomes-a-danish-nationwide-study/363389.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective regarding PSA testing?","Question",{"text":112,"@type":113},"To assess PSA testing and prostate cancer-related outcomes in a national publicly funded healthcare context, with focus on recommendations against PSA testing for asymptomatic men.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were outcomes and PSA testing data obtained?",{"text":117,"@type":113},"Men were identified via Danish national health registries, and PSA tests were extracted from the Danish Register of Laboratory Results and Research using NPU code NPU08669; histology, biopsy-related outcomes, diagnoses, and prostate cancer-specific death were extracted from national pathology and related registers.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about PSA testing rates and age patterns?",{"text":121,"@type":113},"PSA testing rates were high and more prevalent at older ages, including men aged 70–79 years, with measurable cumulative incidence across testing, histology, biopsy, diagnosis, and prostate cancer-specific death pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363389,1790200359,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","BJU Int 2026; 137: 992–999 doi:10.1111/bju.70208  \nOriginal Article  \nProstate-speciﬁc antigen testing and prostate  \ncancer-related outcomes: a Danish nationwide study  \nFrederik K. Palshof1,2 , Lina S. Mørch 1 , Klaus Brasso3,4 , Niels Kroman1,2 , Signe Benzon Larsen1,3,5 , Andreas Røder3,4  and Hein V. Stroomberg3,6   \n1Cancer and Medicine, Danish Cancer Institute, Danish Cancer Society, Copenhagen, 2Department of Breast Surgery, Gentofte Hospital, Hellerup, 3Copenhagen Prostate Cancer Centre, Department of Urology, Rigshospitalet, 4Department of Clinical Medicine, 5Section of Epidemiology, Department of Public Health, University of Copenhagen, and 6Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark  \nObjective  \nTo assess the prostate-speciﬁc antigen (PSA) testing and prostate cancer-related outcomes in a national, publicly funded healthcare setting, with recommendations against testing of asymptomatic men.  \nSubjects and Methods  \nAll men born between 1920 and 1970, alive and residing in Denmark on 1 January 2014, were quarried in the national health registries. Age-standardised rates (ASR) per 100 000 men for men aged >50 years and cumulative incidence at  \n100 years by Aalen Johansen estimator with delayed entry were estimated for PSA testing, prostate histology, biopsy, prostate cancer diagnosis, and prostate cancer-speciﬁc death.  \nResults  \nAmong 1 371 099 eligible men, the ASR of PSA testing in 2023 was 14 659 tests per 100 000 men (95% conﬁdence interval [CI] 14 585–14 733), and 21 828 tests per 100 000 men (95% CI 21 646–22 111) in men aged 70–79 years. Cumulative incidence at 100 years of a PSA test was 84%(95% CI 84–84%), prostate histology 20%(95% CI 20–20%), biopsy 15%(95% CI 15–15%), prostate cancer diagnosis 12%(95% CI 11–12%), and prostate cancer-speciﬁc death 5.0%(95% CI 5.0–5.1%) . The median (interquartile range [IQR]) age at initial PSA test was 60 (52–67) years, 70 (64–76) years at prostate histology and biopsy, 72 (66–78) years at prostate cancer diagnosis, and 84 (78–89) years at prostate cancer-speciﬁc death.  \nConclusions  \nIn Denmark PSA testing rates are high and prevalent in older ages, despite restrictive national guidelines and active training against PSA testing for general practitioners. The ﬁndings support the discussion of whether the availability of the PSA test should be reconsidered to minimise the harms associated with unnecessary testing.  \nKeywords  \nProstate-speciﬁc antigen, prostate cancer, population-based study, epidemiology, real-world evidence, DanProst  \nIntroduction  \nThe introduction of the PSA test in the 1980s fundamentally changed the approach to prostate cancer diagnosis [1] . Once the PSA test became widely available prostate cancer incidence surged while disease-speciﬁc mortality decreased [2] . However, PSA testing leads to substantial overdiagnosis of indolent cancers, resulting in unnecessary biopsies, treatment-related side-effects, and psychological distress [3,4] .  \nIn Denmark, healthcare is publicly funded and universally accessible. For all men a PSA test is accessible through the GP via shared decision-making without cost to the person. However, national and specialty guidelines have long advised against PSA testing, and GPs have been actively trained to avoid unnecessary PSA testing [5] . Nevertheless, politicians, lobby and patient organisations have challenged this practice and have increased awareness of men’s health, including PSA testing.  \n􀀁 2026 The Author(s) .  \n[wileyonlinelibrary.com](wileyonlinelibrary.com) BJU International published by John Wiley & Sons Ltd on behalf of BJU [International. www.bjui.org](International. www.bjui.org)  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \nToday, there is a l","cbCairUY1qg5ey5D","https://ap.wps.com/l/cbCairUY1qg5ey5D","pdf",1221897,"English","# Objective\n# Subjects and Methods\n# Results\n# Conclusions\n# Introduction\n# Subjects and Methods","[{\"question\":\"What was the study objective regarding PSA testing?\",\"answer\":\"To assess PSA testing and prostate cancer-related outcomes in a national publicly funded healthcare context, with focus on recommendations against PSA testing for asymptomatic men.\"},{\"question\":\"How were outcomes and PSA testing data obtained?\",\"answer\":\"Men were identified via Danish national health registries, and PSA tests were extracted from the Danish Register of Laboratory Results and Research using NPU code NPU08669; histology, biopsy-related outcomes, diagnoses, and prostate cancer-specific death were extracted from national pathology and related registers.\"},{\"question\":\"What did the results show about PSA testing rates and age patterns?\",\"answer\":\"PSA testing rates were high and more prevalent at older ages, including men aged 70–79 years, with measurable cumulative incidence across testing, histology, biopsy, diagnosis, and prostate cancer-specific death pathways.\"}]","Prostate-specific antigen testing and prostate cancer-related outcomes: a Danish nationwide study | PDF",1790151031,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/763db4847e7fff7c438dbae8135897af.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3efc1be0a356045d35743f727ee89a15.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/583292cf1089c1fcbd2cebf01c22751c.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d8a13113fa410c88f355a4db50d8cdb.webp",980,1287]